Questions discussed in this category
Do you feel differently about using these in patients with a history of HR-negative breast cancer?
Patients in their later 40s with favorable intermediate-risk prostate cancer s/p 7000cGy/28 EBRT only.
How is your approach different from or similar to those who undergo surgical menopause?
Are there specific vaccines you recommend repeating, or do you recommend a catch-up schedule?
In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients.
18676174061579014232150271495711206101147440
Papers discussed in this category
Curr Oncol Rep,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-08-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-02-01
Obstet Gynecol, 1998 Oct
Acta Oncol, 2019 Apr 08
Scandinavian journal of urology and nephrology, 2004
BJU international, 2005-10
Andrologia, 2017-02
Current opinion in urology, 2007 Nov
JAMA,
JAMA oncology, 2024 Jan 01